Literature DB >> 12684727

Drug use for non-hepatic associated conditions in patients with liver cirrhosis.

M Isabel Lucena1, Raúl J Andrade, Gianni Tognoni, Ramón Hidalgo, Felipe Sanchez de la Cuesta.   

Abstract

AIMS: To study the prescribing patterns of practising physicians for the most frequent non-hepatic associated conditions in patients with liver cirrhosis.
METHODS: A multi-centre prospective observational study carried out in 25 Spanish hospitals. Inpatients admitted to gastrointestinal and liver units with a diagnosis of liver cirrhosis were included in five centrally assigned index days, between February and June 1999. Information was collected about pharmacological treatments used on admission and recommended at discharge.
RESULTS: Five hundred and sixty-eight in-patients with a diagnosis of liver cirrhosis (44% alcoholic cirrhosis) and an average number of 2.5 co-morbid conditions were studied: diabetes mellitus (30%), infectious disorders (24%), cardiovascular disease (20%) and active alcoholism (15%)--the most common associated conditions. Chlormethiazole, amoxicillin-clavulanic acid, paracetamol, gliblenclamide, lorazepam, captopril and tiapride were the drugs used most prevalently. The average prescribed daily dose was <1 defined daily dose per day for most medication classes hepatically handled except for calcium channel blockers.
CONCLUSIONS: The present study expands current knowledge of prescribing patterns for associated conditions in patients with underlying liver cirrhosis. Drug dosing was affected in general by the influence of age and hepatic disease on the disposition of drugs, but knowledge on drug selection needs further attention.

Entities:  

Mesh:

Year:  2003        PMID: 12684727     DOI: 10.1007/s00228-003-0586-2

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  16 in total

1.  Drug utilisation in Dutch nursing homes.

Authors:  K N van Dijk; C S de Vries; P B van den Berg; J R Brouwers; L T de Jong-van den Berg
Journal:  Eur J Clin Pharmacol       Date:  2000-01       Impact factor: 2.953

2.  Hepatotoxicity in patients with cirrhosis, an often unrecognized problem: lessons from a fatal case related to amoxicillin/clavulanic acid.

Authors:  R J Andrade; M I Lucena; M C Fernández; J L Vega; R Camargo
Journal:  Dig Dis Sci       Date:  2001-07       Impact factor: 3.199

3.  Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid.

Authors:  L A García Rodríguez; B H Stricker; H J Zimmerman
Journal:  Arch Intern Med       Date:  1996-06-24

Review 4.  Effects of liver disease on pharmacokinetics. An update.

Authors:  V Rodighiero
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

5.  Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal.

Authors:  M F Mayo-Smith
Journal:  JAMA       Date:  1997-07-09       Impact factor: 56.272

6.  Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis.

Authors:  M Isabel Lucena; Raúl J Andrade; Gianni Tognoni; Ramón Hidalgo; Felipe Sanchez De La Cuesta
Journal:  Eur J Clin Pharmacol       Date:  2002-07-10       Impact factor: 2.953

7.  Patterns of acetaminophen use in alcoholic patients.

Authors:  C F Seifert; D S Lucas; T G Vondracek; D J Kastens; D L McCarty; B Bui
Journal:  Pharmacotherapy       Date:  1993 Jul-Aug       Impact factor: 4.705

8.  Association of acetaminophen hepatotoxicity with fasting and ethanol use.

Authors:  D C Whitcomb; G D Block
Journal:  JAMA       Date:  1994-12-21       Impact factor: 56.272

Review 9.  The rational use of potentially hepatotoxic medications in patients with underlying liver disease.

Authors:  James H Lewis
Journal:  Expert Opin Drug Saf       Date:  2002-07       Impact factor: 4.250

Review 10.  Drug administration in chronic liver disease.

Authors:  J F Westphal; J M Brogard
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.228

View more
  11 in total

1.  Potential drug-drug interactions and adverse drug reactions in patients with liver cirrhosis.

Authors:  Carmen C Franz; Sabin Egger; Christa Born; Alexandra E Rätz Bravo; Stephan Krähenbühl
Journal:  Eur J Clin Pharmacol       Date:  2011-08-13       Impact factor: 2.953

Review 2.  Pharmacokinetic changes of psychotropic drugs in patients with liver disease: implications for dose adaptation.

Authors:  Chantal Schlatter; Sabin S Egger; Lydia Tchambaz; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 3.  Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review.

Authors:  Jonathan G Stine; James H Lewis
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-12-25       Impact factor: 3.869

Review 4.  KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2018-07-09

5.  Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease.

Authors:  April D Lake; Petr Novak; Craig D Fisher; Jonathan P Jackson; Rhiannon N Hardwick; D Dean Billheimer; Walter T Klimecki; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2011-07-07       Impact factor: 3.922

Review 6.  The therapeutic use of analgesics in patients with liver cirrhosis: a literature review and evidence-based recommendations.

Authors:  Farnad Imani; Mahsa Motavaf; Saeid Safari; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2014-10-11       Impact factor: 0.660

7.  The Prescription Pattern of Acetaminophen and Non-Steroidal Anti-Inflammatory Drugs in Patients with Liver Cirrhosis.

Authors:  Young Mi Hong; Ki Tae Yoon; Jeong Heo; Hyun Young Woo; Won Lim; Dae Seong An; Jun Hee Han; Mong Cho
Journal:  J Korean Med Sci       Date:  2016-10       Impact factor: 2.153

Review 8.  Diagnosis and Management of Drug-Induced Liver Injury (DILI) in Patients with Pre-Existing Liver Disease.

Authors:  Rolf Teschke; Gaby Danan
Journal:  Drug Saf       Date:  2016-08       Impact factor: 5.228

Review 9.  Evidence-Based Recommendations to Improve the Safe Use of Drugs in Patients with Liver Cirrhosis.

Authors:  Rianne A Weersink; Margriet Bouma; David M Burger; Joost P H Drenth; S Froukje Harkes-Idzinga; Nicole G M Hunfeld; Herold J Metselaar; Margje H Monster-Simons; Katja Taxis; Sander D Borgsteede
Journal:  Drug Saf       Date:  2018-06       Impact factor: 5.606

10.  Prevalence of Drug Prescriptions and Potential Safety in Patients with Cirrhosis: A Retrospective Real-World Study.

Authors:  Rianne A Weersink; Katja Taxis; Joost P H Drenth; Eline Houben; Herold J Metselaar; Sander D Borgsteede
Journal:  Drug Saf       Date:  2019-04       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.